A Phase 1 interventional study of ACH04 in Diarrhea, sponsored by Ache Laboratorios Farmaceuticos S.A.. Completed at 1 site in Brazil. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-31.
Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 1, Interventional, and Treatment
This study intends to provide information on the safety and tolerability of repeated oral doses of ACH04. A phase I, single-center, first in human, open-label, dose escalation study of ACH04 to assess the safety and tolerability in healthy adults subjects is selected to best address the study goals.
852 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
This study's enrollment of 60 is below the median of 136 across 713 interventional studies indexed under Diarrhea.
Browse Diarrhea studies →Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 34 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dosage: 1 capsule, PO, 24/24h for 10 days.
Drug: ACH04
The subjects will receive the study medication in each group
Evaluate the safety of rising multiple doses of ACH04
Evaluate the occurrence of adverse events, Assess safety through laboratory tests and Assess safety through electrocardiogram
Time frame: up to 39 days
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ache Laboratorios Farmaceuticos S.A.